Literature DB >> 33467481

Osteosarcoma Pathogenesis Leads the Way to New Target Treatments.

Isabel Fernandes1,2, Cecília Melo-Alvim1, Raquel Lopes-Brás1, Miguel Esperança-Martins1,2,3, Luís Costa1,2.   

Abstract

Osteosarcoma (OS) is a rare condition with very poor prognosis in a metastatic setting. Basic research has enabled a better understanding of OS pathogenesis and the discovery of new potential therapeutic targets. Phase I and II clinical trials are already ongoing, with some promising results for these patients. This article reviews OS pathogenesis and new potential therapeutic targets.

Entities:  

Keywords:  molecular targets; osteosarcoma; pathogenesis

Mesh：

Substances：

Year:  2021        PMID： 33467481      PMCID： PMC7831017          DOI： 10.3390/ijms22020813

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN： 1422-0067            Impact factor:   5.923


  98 in total

1.  Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption.

Authors:  Francois Lamoureux; Peggy Richard; Yohann Wittrant; Séverine Battaglia; Paul Pilet; Valérie Trichet; Frédéric Blanchard; Francois Gouin; Bruno Pitard; Dominique Heymann; Francoise Redini
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

Review 2.  Chemotherapy resistance in osteosarcoma: current challenges and future directions.

Authors:  Alexander J Chou; Richard Gorlick
Journal:  Expert Rev Anticancer Ther       Date:  2006-07       Impact factor: 4.512

Review 3.  Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis.

Authors:  L C Hofbauer; A E Heufelder
Journal:  Eur J Endocrinol       Date:  1998-08       Impact factor: 6.664

4.  Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival.

Authors:  A Sérgio Petrilli; Beatriz de Camargo; Vicente Odone Filho; Paula Bruniera; Algemir L Brunetto; Reynaldo Jesus-Garcia; Olavo P Camargo; Walter Pena; Pedro Péricles; Alexandre Davi; José D Prospero; Maria Teresa S Alves; Claudia R Oliveira; Carla R D Macedo; Wellington L Mendes; Maria Teresa A Almeida; Maria L Borsato; Telma M dos Santos; Jorge Ortega; Elio Consentino
Journal:  J Clin Oncol       Date:  2006-03-01       Impact factor: 44.544

Review 5.  Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis.

Authors:  Masabumi Shibuya; Lena Claesson-Welsh
Journal:  Exp Cell Res       Date:  2005-12-05       Impact factor: 3.905

Review 6.  Targeted therapies in bone sarcomas.

Authors:  K Scotlandi; P Picci; H Kovar
Journal:  Curr Cancer Drug Targets       Date:  2009-11       Impact factor: 3.428

7.  Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.

Authors:  Yun-Rong Zhu; Han Min; Jian-Feng Fang; Feng Zhou; Xiong-Wei Deng; Yun-Qing Zhang
Journal:  Cancer Biol Ther       Date:  2015-04-14       Impact factor: 4.742

8.  Ribosomal protein S3 regulates GLI2-mediated osteosarcoma invasion.

Authors:  Hiroko Nagao-Kitamoto; Takao Setoguchi; Sho Kitamoto; Shunsuke Nakamura; Arisa Tsuru; Masahito Nagata; Satoshi Nagano; Yasuhiro Ishidou; Masahiro Yokouchi; Shinichi Kitajima; Takako Yoshioka; Shingo Maeda; Suguru Yonezawa; Setsuro Komiya
Journal:  Cancer Lett       Date:  2014-11-11       Impact factor: 8.679

9.  Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression.

Authors:  L H Chan; W Wang; W Yeung; Y Deng; P Yuan; K K Mak
Journal:  Oncogene       Date:  2013-10-21       Impact factor: 9.867

Review 10.  A highlight on Sonic hedgehog pathway.

Authors:  Gabriela Basile Carballo; Jéssica Ribeiro Honorato; Giselle Pinto Farias de Lopes; Tania Cristina Leite de Sampaio E Spohr
Journal:  Cell Commun Signal       Date:  2018-03-20       Impact factor: 5.712
View more
  6 in total

1.  Epithelial to Mesenchymal Transition Relevant Subtypes with Distinct Prognosis and Responses to Chemo- or Immunotherapies in Osteosarcoma.

Authors:  Yang Zhou; Gai Li; Hu Li; Fuchong Lai; Pingguo Duan; Ming Cheng
Journal:  J Immunol Res       Date:  2022-07-04       Impact factor: 4.493

2.  Single-cell RNA-seq identification of four differentially expressed survival-related genes by a TARGET: Osteosarcoma database analysis.

Authors:  Mesalie Feleke; Wenyu Feng; Emel Rothzerg; Dezhi Song; Qingjun Wei; Sulev Kõks; David Wood; Yun Liu; Jiake Xu
Journal:  Exp Biol Med (Maywood)       Date:  2022-03-12

Review 3.  Role of MicroRNAs in Human Osteosarcoma: Future Perspectives.

Authors:  Lola Llobat; Olivia Gourbault
Journal:  Biomedicines       Date:  2021-04-23

4.  LncRNA KASRT Serves as a Potential Treatment Target by Regulating SRSF1-Related KLF6 Alternative Splicing and the P21/CCND1 Pathway in Osteosarcoma: An In Vitro and In Vivo Study.

Authors:  Kai Chen; Cheng Li; Shuai Huang; Yu Chen; Xiaodong Zhu
Journal:  Front Oncol       Date:  2021-09-09       Impact factor: 6.244

5.  circUSP34 accelerates osteosarcoma malignant progression by sponging miR-16-5p.

Authors:  Jingbing Lou; Hongliang Zhang; Jiuhui Xu; Tingting Ren; Yi Huang; Xiaodong Tang; Wei Guo
Journal:  Cancer Sci       Date:  2021-11-22       Impact factor: 6.716

Review 6.  Chemoresistance-Related Stem Cell Signaling in Osteosarcoma and Its Plausible Contribution to Poor Therapeutic Response: A Discussion That Still Matters.

Authors:  Sara R Martins-Neves; Gabriela Sampaio-Ribeiro; Célia M F Gomes
Journal:  Int J Mol Sci       Date:  2022-09-27       Impact factor: 6.208
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.